Zum Inhalt springen Zur Suche springen

News-Detail

Rituximab as First-Line Compared to Escalation Immunotherapy Is Associated With Lower Disability Accumulation in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Multicenter Cohort Study From Germany and the United Kingdom.
Daniel Engels et al., Eur J Neurol. 2025

Daniel Engels, Chiara Rocchi, Mirasol Forcadela, Pakeeran Siriratnam, Marius Ringelstein, Martin W Hümmert, Katrin Giglhuber, Achim Berthele, Corinna Trebst, Orhan Aktas, Joachim Havla, Saif Huda, Tania Kümpfel

Rituximab as First-Line Compared to Escalation Immunotherapy Is Associated With Lower Disability Accumulation in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Multicenter Cohort Study From Germany and the United Kingdom.

Eur J Neurol. 2025 Jun;32(6):e70243. doi: 10.1111/ene.70243. PubMed ID: 40492480

 

Further Information:

DOI: 10.1111/ene.70243

Orhan Aktas

Kategorie/n: NND-Publikationen